Overview


According to FutureWise analysis the market for anti-infective vaccines in 2023 is US$ 64.57 billion, and is expected to reach US$ 165.91 billion by 2031 at a CAGR of 12.50%.

Anti-infective vaccines, also known as infectious disease vaccines, are medical interventions developed to prevent the spread of infectious diseases caused by specific microorganisms such as bacteria, viruses, parasites, or others. These vaccines boost the immune system to produce an immune response without causing the disease, resulting in immunity against the targeted infectious agent, and are one of the most cost-effective investments in health and economic development. Immunization can prevent suffering and death from infectious diseases like polio, measles, and pneumonia. In 1796, Edward Jenner invented the first vaccine using cowpox to inoculate against smallpox. His groundbreaking work ultimately led to the global eradication of smallpox, officially declared in 1980. Since then, vaccines have helped to suppress the spread of several infectious diseases, including polio.

Live attenuated vaccines contain complete viruses or bacteria that have been deliberately weakened (attenuated) to elicit an immune response without causing illness in healthy individuals. For most modern vaccines, this "weakening" is acquired through genetic modification of the pathogen, either through naturally occurring change or as an alteration introduced by scientists. These vaccines are known for inducing robust and long-lasting immune responses, making them among the most effective options available. However, live vaccines may not be suitable for individuals whose immune system doesn't work due to drug treatment or underlying health conditions. This is because the weakened pathogens could potentially reproduce excessively and lead to illness in these individuals.

FutureWise Market Research has published a report that provides an insightful analysis anti-infective vaccines market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, anti-infective vaccines market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Emergent BioDefense Operations Lansing Inc.
  • Sanofi Pasteur
  • MerckCo.
  • MedImmune LLC.
  • Novartis Vaccines
  • Diagnostics Ltd.
  • Intercell Biomedical
  • MassBiologics
  • Barr Labs, Inc.
  • Organon Teknika Co.
  • Emergent BioDefense Operations Lansing Inc.
  • CSL Ltd.
  • ID Biomedical Co.
  • Protein Sciences Co.
  • Wyeth Pharmaceuticals, Inc.
  • Berna Biotech

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Anti-Infective Vaccines Market:

  • In Oct 2022 - Merck expanded its vaccine manufacturing facility in Elkton, VA.

  • In March 2022 - Bharat Biotech collaborated with BIOFABRI to develop, produce, and promote a novel tuberculosis vaccine across over 70 countries throughout sub-Saharan Africa & Southeast Asia.

The rising awareness about the significance of vaccination and the prevention of infectious diseases will likely drive the demand for anti-infective vaccines market. As societies increasingly grasp the essentiality of immunization in reducing health risks and fostering well-being, an increasing demand for these preventive measures is foreseen. This increased awareness is anticipated to catalyze proactive efforts toward disease prevention, driving the imperative for accessible and effective anti-infective vaccines. Moreover, certain programs provided by government initiatives, vaccination programs, targeted immunization campaigns, and substantial financial support directed toward the research and development of anti-infective vaccines serve as a potential driver in propelling market expansion. Through strategic partnerships and investment, governments contribute to a conducive environment for innovation, affordability, and accessibility of these vital preventive solutions. This proactive engagement fosters surroundings that prioritizes public health and bolsters the growth of the anti-infective vaccines market during the projected period. Furthermore, the lack of vaccine education and acceptance of embracing immunization may hinder the widespread adoption of the anti-infective vaccines market. The absence of proper information dissemination regarding vaccine safety concerns and religious disbelief impairs the widespread adoption of preventive measures. This educational barrier poses challenges to achieving optimal vaccine coverage, potentially impeding effective disease control and mitigation efforts.

By Product Type

  • Live/Attenuated Vaccines
  • Inactivated Vaccines
  • DNA and Recombinant Vector Vaccines
  • Others

By Disease Type

  • Bacterial Diseases
    • Typhoid Vaccines
    • Tuberculosis Vaccines
    • Tetanus and Diphtheria Vaccines
    • Others
  • Viral Diseases
    • Influenza Vaccines
    • Hepatitis Vaccines
    • Polio Vaccines
    • Others

By Distribution Channel

  • Hospitals Clinics
  • Public Hospitals
  • Private Clinics
  • Retail Pharmacies and Drug Stores
  • E-commerce

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. It is driven by well-established healthcare infrastructure, high awareness about vaccination, and government-supported immunization programs. Furthermore, Key players are opting for strategies such as joint ventures, mergers, acquisitions, partnerships, new product launches, and facility expansion to strengthen their market position in the anti-infective vaccines market. For instance, in May 2022, Affinivax, Inc. (Affinivax) joined into an acquisition agreement to be acquired by GSK plc for a US$2.1 billion upfront amount & approximately US$1.2 billion in potential development milestones. The most advanced vaccines in this new class are next-generation pneumococcal vaccines developed by Affinivax. The above mentione factors are expected to drive the growth of anti-infective vaccine market during the forecast period in the region.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Anti-Infective Vaccines Market By Product Type, By Disease Type, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Anti-Infective Vaccines Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Anti-Infective Vaccines Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Anti-Infective Vaccines Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Anti-Infective Vaccines Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Live/Attenuated Vaccines
        2. Inactivated Vaccines
        3. DNA and Recombinant Vector Vaccines
        4. Others

  • 8.   Anti-Infective Vaccines Market, By Disease Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Bacterial Diseases
         1.1. Typhoid Vaccines
         1.2. Tuberculosis Vaccines
         1.3. Tetanus and Diphtheria Vaccines
         1.4. Others
        2. Viral Diseases
         2.1. Influenza Vaccines
         2.2. Hepatitis Vaccines
         2.3. Polio Vaccines
         2.4. Others

  • 9.   Anti-Infective Vaccines Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals Clinics
        2. Public Hospitals
        3. Private Clinics
        4. Retail Pharmacies and Drug Stores
        5. E-commerce

  • 10.   North America Anti-Infective Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Anti-Infective Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Anti-Infective Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Anti-Infective Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Emergent BioDefense Operations Lansing Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Sanofi Pasteur
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. MerckCo.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. MedImmune LLC.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Novartis Vaccines
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Diagnostics Ltd.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Intercell Biomedical
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. MassBiologics
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Barr Labs, Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10.Organon Teknika Co.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11.Emergent BioDefense Operations Lansing Inc.
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12.CSL Ltd.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13.ID Biomedical Co.
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14.Protein Sciences Co.
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15.Wyeth Pharmaceuticals, Inc.
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16.Berna Biotech
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client

Related Market

Anti-Infective Ophthalmic Market

Read More

Veterinary Anti-infectives Market

Read More

Anti Infective Drugs Market

Read More

Anti-Infective Endotracheal Tube Market

Read More
Partner

Our Clients